E815
TEAS SECTION 8 & 15 RECEIVED
23/06/2026
Voltar para busca
Dado oficial do USPTO
MEDINCELL
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
26
Atualização mais recente
24/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
26/04/2019
Data de registro
16/06/2020
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
16/06/2020
Última transação
24/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
Jacou, FR
Examinador
IM, JEAN H
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
MedinCell S.A.
Representantes
Stephen P. McNamara ST. ONGE STEWARD JOHNSTON & REENS LLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations and substances for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; pharmaceutical preparationsa drug delivery system comprising pharmaceutical compositions for subcutaneous or intraarticular administration for the continuous release of therapeutic agents for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; veterinary preparations and substances for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; veterinary preparationsa drug delivery system comprising compositions that facilitate continuous release delivery of a wide variety of therapeutic subcutaneous or intraarticular veterinary agents; pharmaceutical compositions for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceutical and veterinary pharmaceutical preparations; Drug delivery agents in the form of compounds that facilitate controlled release delivery of subcutaneous or intraarticular active ingredients for a wide variety of pharmaceuticals and veterinary pharmaceutical preparations; Drug delivery agents in the form of drug delivery compounds that facilitate sustained or extended release of the active ingredients for a wide variety of pharmaceuticals and veterinary pharmaceutical preparations; Drug delivery agents in the form of compounds that facilitate delivery of injectable pharmaceutical and veterinary pharmaceutical preparations; sustained or extended release drug delivery agents being compounds used to facilitate delivery of drugssold as an integral component of pharmaceutical and veterinary pharmaceutical preparations for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; chemical preparations for medical or pharmaceutical use for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; Carriers and mediums being drug delivery agents comprised of compounds for facilitating the delivery of pharmaceutical and veterinary pharmaceutical preparations for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders; pharmaceutical and veterinary pharmaceutical preparations and substances for subcutaneous delivery for use in contraceptionfor the treatment of infectiousgeneticmetabolicendocrinecardiovascularoncologicalinflammatoryrespiratoryneurologicalhormonal and cognitive diseases and disordersfor the treatment of substance abuse related diseases and disorders
Publicações
Histórico de despachos e eventos da marca no USPTO.
26 publicações encontradas
E815
TEAS SECTION 8 & 15 RECEIVED
03/06/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
16/06/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
16/06/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
31/03/2020
PUBO
PUBLISHED FOR OPPOSITION
31/03/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/03/2020
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
27/02/2020
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
07/02/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
31/01/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
31/01/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
31/01/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
31/01/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
31/01/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/01/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/01/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/01/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/07/2019
GNRT
NON-FINAL ACTION E-MAILED
10/07/2019
CNRT
NON-FINAL ACTION WRITTEN
10/07/2019
DOCK
ASSIGNED TO EXAMINER
09/07/2019
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
23/05/2019
ALIE
ASSIGNED TO LIE
19/05/2019
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
13/05/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
13/05/2019
NWAP
NEW APPLICATION ENTERED
30/04/2019
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MEDINCELL ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.